Every 8-K that Gilead Sciences Inc (GILD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow GILD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GILD filings page.
Gilead Sciences reported strong base-business growth but a large loss for the quarter ended June 30, 2026. Total revenues rose 10% to $7.8 billion, with product sales excluding Veklury up 10% to $7.6 billion, led by 12% HIV growth and higher Trodelvy and Livdelzi sales.
GAAP net loss was $10.5 billion, or $(8.45) per share, versus earnings of $1.56 a year earlier, mainly from $11.2 billion of acquired IPR&D expenses tied to the Arcellx, Tubulis and Ouro Medicines acquisitions and a $1.75 billion IPR&D impairment of Immunomedics assets. Non-GAAP diluted loss per share was $(6.75), down from $2.01.
Cash, cash equivalents and marketable debt securities were $3.2 billion as of June 30, 2026, down from $10.6 billion at year-end after $11.3 billion of acquisition outflows, $2.8 billion of debt repayments and ongoing dividends and buybacks. Management now guides 2026 product sales to $30.1–$30.4 billion, with Veklury around $300 million, and expects a full-year GAAP diluted loss per share of $(3.75) to $(3.40).
Gilead Sciences, Inc. entered into an Eleventh Supplemental Indenture to support a new multi-tranche senior notes offering under its existing base indenture. The company issued 4.250% Senior Notes due 2028 with an aggregate principal amount of $500,000,000 and 4.400% Senior Notes due 2029 with an aggregate principal amount of $1,000,000,000.
It also issued 4.600% Senior Notes due 2031 with an aggregate principal amount of $1,000,000,000 and 4.900% Senior Notes due 2034 with an aggregate principal amount of $500,000,000. These notes were sold in a public offering from an effective Form S-3 shelf, with semi-annual interest payments until their respective maturities. Gilead plans to use the net proceeds for general corporate purposes, including potential acquisitions, investments, strategic transactions or other business opportunities.
Gilead Sciences reported first quarter 2026 revenue of $6.96 billion, up 4% year over year, driven by 10% HIV growth to $5.03 billion and strong contributions from Trodelvy and Livdelzi, partly offset by a 52% decline in Veklury to $144 million and softer Cell Therapy sales.
GAAP diluted EPS rose to $1.61 from $1.04, and non-GAAP diluted EPS increased to $2.03 from $1.81, helped by higher product sales, net unrealized gains on equity securities, and lower acquired IPR&D expenses.
For full year 2026, Gilead raised product sales guidance to $30.0–$30.4 billion and product sales excluding Veklury to $29.4–$29.8 billion, but now expects a GAAP diluted loss per share of $(3.25) to $(2.85) and a non-GAAP diluted loss per share of $(1.05) to $(0.65), primarily due to $11.5 billion anticipated acquired IPR&D charges and financing costs tied to the Arcellx, Ouro and Tubulis transactions.
Gilead Sciences, Inc. held its 2026 annual stockholder meeting, where a quorum was reached with 1,130,179,690 of 1,241,222,013 entitled shares represented. Stockholders elected nine directors for one-year terms and ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Stockholders approved, on an advisory basis, compensation for Named Executive Officers and also approved the amended and restated 2022 Equity Incentive Plan. Three stockholder proposals—calling for an independent Board Chair policy, a report on extended patent exclusivities and patient access, and a report on ESG and DEI compensation metrics—did not receive approval.
Gilead Sciences has completed its acquisition of Arcellx, gaining full control of anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T therapy for multiple myeloma. Gilead is paying $115 in cash per Arcellx share plus a non-transferable $5 contingent value right (CVR) per share.
The deal implies total equity value of about $7.8 billion and required roughly $7.1 billion of cash to close, including equity awards and related payments. About 38.8 million Arcellx shares, representing 77.2% of outstanding shares, were tendered before a follow-on merger made Arcellx a wholly owned Gilead subsidiary.
The CVR pays $5 in cash per share if cumulative global net sales of anito-cel reach $6.0 billion from launch through the end of 2029. Gilead expects to account for the transaction as an asset acquisition and estimates the deal will reduce 2026 diluted EPS by approximately $5.57 to $5.67, be modestly dilutive in 2026 and 2027 excluding acquired R&D, and become accretive in 2028 and later if anito-cel receives FDA approval.
Gilead Sciences plans to acquire Arcellx through a tender offer for $115.00 per share in cash plus a $5.00 contingent value right (CVR) per share, implying equity value of $7.8 billion. Each CVR pays $5.00 in cash if cumulative worldwide sales of anitocabtagene autoleucel (anito-cel) reach $6.0 billion by December 31, 2029.
A Gilead subsidiary will launch a tender offer for all Arcellx shares it does not already own, needing more than 50% of outstanding shares, with customary antitrust and other closing conditions. Gilead currently owns about 11.5% of Arcellx, and support agreements cover an additional 10.3% of shares.
Following successful completion of the offer, Arcellx will merge into the Gilead subsidiary, and remaining shares will receive the same cash and CVR consideration. Anito-cel’s Biologic License Application for fourth-line relapsed or refractory multiple myeloma has been accepted by the FDA, with a Prescription Drug User Fee Act action date of December 23, 2026, and Gilead expects the deal to be accretive to earnings per share in 2028 and beyond upon FDA approval.
Gilead Sciences reported higher fourth quarter and full-year 2025 results, driven mainly by its HIV and liver disease portfolios. Q4 2025 revenue rose 5% to $7.9 billion, and diluted EPS increased to $1.74. Full-year 2025 revenue grew 2% to $29.4 billion, with diluted EPS jumping to $6.78 from $0.38, helped by lower IPR&D charges, higher product sales and lower SG&A.
Product sales excluding Veklury increased 4% to $28.0 billion in 2025. HIV sales grew 6% to $20.8 billion, including Biktarvy up 7% to $14.3 billion and Descovy up 31% to $2.8 billion. Liver disease sales rose 6% to $3.2 billion, while Veklury declined 49% to $911 million as COVID-19 hospitalizations fell.
Non-GAAP diluted EPS for 2025 was $8.15, up from $4.62, reflecting strong underlying profitability. Gilead generated $10.0 billion in operating cash flow during 2025, maintained product gross margin near 78% on a GAAP basis and 86% on a non-GAAP basis, and ended the year with $10.6 billion in cash, cash equivalents and marketable debt securities.
For full-year 2026, Gilead projects product sales of $29.6–$30.0 billion, including Veklury of $600 million, and diluted EPS of $6.75–$7.15, with non-GAAP diluted EPS of $8.45–$8.85. The company highlighted continued launches such as Yeztugo for HIV prevention and Livdelzi for liver disease, as well as planned oncology and HIV pipeline launches.
Gilead Sciences reported a leadership change affecting its legal and corporate affairs functions. The company announced that Deborah H. Telman will no longer serve as Executive Vice President, Corporate Affairs and General Counsel as of December 5, 2025. Her employment with the company will end later in December. This transition means Gilead will need to adjust leadership responsibilities in a key oversight and governance role, which can influence how the company manages legal risk, regulatory matters and external corporate communications.
Gilead Sciences announced its financial results for the quarter ended September 30, 2025 and furnished a press release as Exhibit 99.1.
The company presented GAAP and non-GAAP measures, with reconciliations provided in the press release tables. The information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed “filed” under the Exchange Act, nor incorporated by reference.
Gilead Sciences, Inc. has entered into settlement agreements to resolve patent litigation over its HIV treatment Biktarvy with generic manufacturers Lupin Ltd., Cipla Ltd. and Laurus Labs Ltd. These companies had sought U.S. approval to sell generic versions of Biktarvy.
Under the agreements, which include standard acceleration provisions, no generic entry is expected in the United States before April 1, 2036 for Biktarvy tablets containing bictegravir 50 mg, emtricitabine 200 mg and tenofovir alafenamide 25 mg. Gilead also reiterates that these statements are forward-looking and subject to risks such as intellectual property challenges, litigation outcomes and regulatory changes.